Syndrome d'emphysème des sommets et fibrose pulmonaire des bases combinés

Cottin, Vincent; Brillet, Pierre-Yves; Nunès, Hilario; Cordier, Jean-François

doi:10.1016/j.lpm.2007.03.005

Cited by 27 publications

(30 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…85 In addition, patients with combined pulmonary fi brosis and emphysema syndrome have a poor prognosis, which might be associated with higher pulmonary vascular resistance and PH. [86][87][88] Gastroesophageal refl ux disease (GERD) is also a common comorbidity in patients with IPF, 73 and the likelihood of having both IPF and GERD increases in patients . 60 years of age.…”

Section: Environmental Factors and Ipfmentioning

confidence: 99%

Workshop on Idiopathic Pulmonary Fibrosis in Older Adults

Castriotta

Eldadah

Foster

et al. 2010

Chest

View full text Add to dashboard Cite

T he aging lung loses mass and undergoes several functional and structural changes ( Table 1 ). Lung function declines with age, as shown by changes in gas exchange and airfl ow limitation ( Fig 1 ). Older adults, defi ned as those aged Ն 60 years, become more rapidly limited during exercise, and 50% of adults . 70 years of age become exercise-limited by dyspnea, compared with only 20% of younger adults. Abbreviations: EBV 5 Epstein-Barr virus; EMT 5 epithelial-mesenchymal transition; ER 5 endoplasmic reticulum; GERD 5 gastroesophageal refl ux disease; IPF 5 idiopathic pulmonary fi brosis; MSC 5 mesenchymal stem cell; PH 5 pulmonary hypertension; SP-C 5 surfactant protein C; TERT 5 telomerase reverse transcriptase; TGF-b 5 transforming growth factor b ; UIP 5 usual interstitial pneumonia

show abstract

Section: Environmental Factors and Ipfmentioning

confidence: 99%

Workshop on Idiopathic Pulmonary Fibrosis in Older Adults

Castriotta

Eldadah

Foster

et al. 2010

Chest

View full text Add to dashboard Cite

show abstract

“…For instance, in cancer and Biomarkers of COPD and IPF COPD and IPF share cigarette smoking as a common dominant risk factor for their development. Although emphysema and pulmonary fibrosis can coexist in the same individual, 20 recent evidence suggests that these patterns of disease may be distinct consequences of smoking that refl ect unique individual susceptibilities. 21 We have shown that interstitial lung abnormalities are inversely associated with total lung capacity and the severity of radiographic emphysema in smokers, suggesting that smoking may lead to two distinct patterns of injury.…”

Section: Potential Biomarker Applicationsmentioning

confidence: 99%

“…These individuals are often men with severe dyspnea on exertion, relatively preserved lung volumes, and marked reductions in diffusing capac ity. 20,22 Patients with combined COPD and IPF have a high prevalence of pulmonary arterial hypertension and lung cancer and are at a greater risk of death than are those with IPF alone. 23 It is theorized that lung-based protein biomark ers can be investigated in peripheral blood because changes in markers in the blood may refl ect lung biology.…”

Section: Potential Biomarker Applicationsmentioning

confidence: 99%

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Doyle

Pinto-Plata

Morse

et al. 2012

Chest

View full text Add to dashboard Cite

Recent advances in the fi eld of clinical biomarkers suggest that quantifi cation of serum proteins could play an important role in the diagnosis, classifi cation, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fi brosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals . In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.CHEST 2012; 142(4):1027-1034Abbreviations: BODE 5 BMI, airfl ow obstruction, dyspnea, and exercise capacity; CCL-18 5 CC-chemokine ligand-18; CRP 5 C-reactive protein; IPF 5 idiopathic pulmonary fi brosis; KL-6 5 Krebs von den Lungen-6; MMP 5 matrix metalloproteinase; SP 5 surfactant protein; TNF-a 5 tumor necrosis factor-a

show abstract

“…Les échanges gazeux sont très altérés (abaissement majeur du transfert du CO, hypoxémie d'exercice). Le diagnostic repose sur la TDM thoracique, qui montre un emphysème centrolobulaire et/ou bulleux des sommets pulmonaires (très souvent associé à un emphysème paraseptal évocateur), et des opacités évocatrices de fibrose des bases (comportant un peu plus fréquemment des opacités en verre dépoli qu'au cours de la fibrose pulmonaire idiopathique) [34]. Une hypertension pulmonaire associée est fréquente et de pronostic défavorable.…”

Section: Exacerbations De Fibrose Pulmonaire Idiopathiqueunclassified

Fibrose pulmonaire idiopathique

Cottin

2008

La Presse Médicale

Self Cite

View full text Add to dashboard Cite

Syndrome d'emphysème des sommets et fibrose pulmonaire des bases combinés

Cited by 27 publications

References 57 publications

Workshop on Idiopathic Pulmonary Fibrosis in Older Adults

Workshop on Idiopathic Pulmonary Fibrosis in Older Adults

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Fibrose pulmonaire idiopathique

Contact Info

Product

Resources

About